Replies to post #204211 on Biotech Values

[dewophile]

I first wondered whether they wanted to have the Achillion compound removed from half of the tablets to save on licensing costs

not only would this be impractical, there would be risk of pts taking the wrong pill and getting too much or too little drug. the whole point of a FDC is to improve compliance and hence safety/efficacy. also achn would not get a lower royalty based on dosing schedule, although they may get lower if JNJ uses a 3DAA vs 2DAA (i am not familiar with the terms they struck)

note the 75mg dose of olysio is half the approved dose. speaking of olysio this is obviously bullish for medivir since olysio now has new life